FDA as a catalyst for translation-Reference-Cited by-同舟云学术

FDA as a catalyst for translation

Published:2015-07-15 Issue:296 Volume:7 Page:
ISSN:1946-6234
Container-title:Science Translational Medicine
language:en
Short-container-title:Sci. Transl. Med.

Author:

Califf Robert M.¹²,Ostroff Stephen¹²

Affiliation:

1. Robert M. Califf is Deputy Commissioner for Medical Products and Tobacco at the U.S. Food and Drug Administration (FDA), U.S. Department of Health and Human Services, Silver Spring, MD 20993, USA.

2. Stephen Ostroff is Acting Commissioner at FDA, U.S. Department of Health and Human Services, Silver Spring, MD 20993, USA.

Abstract

The FDA seeks to leverage modern scientific and technological knowledge to accelerate translation.

Publisher

American Association for the Advancement of Science (AAAS)

Subject

General Medicine

Reference8 articles.

1. FDA science and mission at risk: Report of the subcommittee on science and technology (November 2007); available at www.fda.gov/ohrms/dockets/AC/07/briefing/2007-4329b_02_01_FDA%20Report%20on%20Science%20and%20Technology.pdf.

2. Advancing regulatory science at FDA: A strategic plan (August 2011); available at www.fda.gov/downloads/ScienceResearch/SpecialTopics/RegulatoryScience/UCM268225.pdf.

3. A New Initiative on Precision Medicine

4. 21 st Century Cures: A Call to Action (U.S. House of Representatives Energy and Commerce Committee Washington .DC 2014); available at http://energycommerce.house.gov/sites/republicans.energycommerce.house.gov/files/analysis/21stCenturyCures/20140501WhitePaper.pdf.

5. Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework;Biomarkers definitions working group;Clin. Pharmacol. Ther.,2001

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetic and Pharmacodynamic Obstacles for Phage Therapy From the Perspective of Clinical Practice;Clinical Infectious Diseases;2023-11-01

2. Current Updates from the Long-Standing Phage Research Centers in Georgia, Poland, and Russia;Bacteriophages;2021

3. The evolution of patient-focused drug development and Duchenne muscular dystrophy;Expert Review of Pharmacoeconomics & Outcomes Research;2020-01-02

4. Clinical translation of the assets of biomedical engineering – a retrospective analysis with looks to the future;Expert Review of Medical Devices;2019-10-31

5. Phage Therapy: What Have We Learned?;Viruses;2018-05-28